Lipocine Inc(NASDAQ:LPCN) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.32. Analysts had estimated an EPS of $-0.37.
Lipocine Inc (LPCN) shares turned negative on Wednesdays trading session with the shares closing down -0.15 points or -3.74% at a volume of 1,31,884. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $4.15. The peak price level was also seen at $4.15 while the days lowest was $3.76. Finally the shares closed at $3.86. The 52-week high of the shares is $19.23 while the 52-week low is $2.51. According to the latest information available, the market cap of the company is $70 M.
Several Insider Transactions has been reported to the SEC. On Oct 2, 2015, John W. Higuchi (director) purchased 5,000 shares at $12.68 per share price.Also, On Oct 2, 2015, Mahesh V. Patel (CEO) purchased 4,000 shares at $11.78 per share price.
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company’s primary development programs are based on oral delivery solutions for bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements bypass first-pass metabolism reduce side effects and eliminate gastrointestinal interactions that limit bioavailability. The Company’s lead product candidate LPCN 1021 is an oral testosterone replacement therapy (TRT) designed for twice-a-day dosing and is in Phase III testing. Additional pipeline candidates include LPCN 1111 an oral testosterone therapy product targeted for once daily dosing which is in Phase II testing and LPCN 1107 an oral therapy for the prevention of preterm birth which is in Phase I testing.